دورية أكاديمية
Xanthophyll β-cryptoxanthin treatment inhibits hepatic steatosis without altering vitamin A status in β-carotene 9',10'-oxygenase knockout mice.
| العنوان: | Xanthophyll β-cryptoxanthin treatment inhibits hepatic steatosis without altering vitamin A status in β-carotene 9',10'-oxygenase knockout mice. |
|---|---|
| المؤلفون: | Liu C; Nutrition and Cancer Biology Laboratory, JM USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA., Rafacho BPM; Nutrition and Cancer Biology Laboratory, JM USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA., Wang XD; Nutrition and Cancer Biology Laboratory, JM USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA. |
| المصدر: | Hepatobiliary surgery and nutrition [Hepatobiliary Surg Nutr] 2022 Apr; Vol. 11 (2), pp. 188-198. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: AME Publishing Company Country of Publication: China (Republic : 1949- ) NLM ID: 101600750 Publication Model: Print Cited Medium: Print ISSN: 2304-3881 (Print) Linking ISSN: 23043881 NLM ISO Abbreviation: Hepatobiliary Surg Nutr Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Hong Kong : AME Publishing Company |
| مستخلص: | Background: β-cryptoxanthin (BCX), one of the major carotenoids detected in human circulation, can protect against the development of fatty liver disease. BCX can be metabolized through β-carotene-15,15'-oxygenase (BCO1) and β-carotene-9',10'-oxygenase (BCO2) cleavage pathways to produce both vitamin A and apo-carotenoids, respectively, which are considered important signaling molecules in a variety of biological processes. Recently, we have demonstrated that BCX treatment reduced hepatic steatosis severity and hepatic total cholesterol levels in both wide type and BCO1 -/- /BCO2 -/- double knock out (KO) mice. Whether the protective effect of BCX is seen in single BCO2 -/- KO mice is unclear. Methods: In the present study, male BCO2 -/- KO mice at 1 and 5 months of age were assigned to two groups by age and weight-matching as follows: (I) -BCX control diet alone (AIN-93 purified diets); (II) +BCX 10 mg (supplemented with 10 mg of BCX/kg of diet) for 3 months. At 4 and 8 months of age, hepatic steatosis and inflammatory foci were evaluated by histopathology. Retinoids and BCX concentrations in liver tissue were analyzed by high-performance liquid chromatography (HPLC). Hepatic protein expressions of SIRT1, acetylated and total FoxO1, PGC1α, and PPARα were determined by the Western blot analysis. Real-time PCR for gene expressions ( MCAD , SCD1 , FAS , TNFα , and IL-1β gene expression relative to β-actin) was conducted in the liver. Results: Steatosis was detected at 8 months but not at 4 months of age. Moreover, BCX supplementation significantly reduced the severity of steatosis in the livers of BCO2 KO mice, which was associated with changes in hepatic SIRT1 acetylation of FOXO1, PGC1α protein expression and PPARα protein expression in BCO2 -/- KO mice. HPLC analysis showed that hepatic BCX was detected in BCX supplemented groups, but there were no differences in the hepatic levels of retinol and retinyl palmitate (RP) among all groups. Conclusions: The present study provided experimental evidence that BCX intervention can reduce liver steatosis independent of BCO2. Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-20-404/coif). XDW serves as the unpaid Deputy Editor-in-Chief of Hepatobiliary Surgery and Nutrition. The other authors have no conflicts of interest to declare. (2022 Hepatobiliary Surgery and Nutrition. All rights reserved.) |
| التعليقات: | Comment in: Hepatobiliary Surg Nutr. 2023 Jun 1;12(3):450-452. (PMID: 37351127) |
| References: | Cell Metab. 2009 Apr;9(4):327-38. (PMID: 19356714) Cancer Lett. 2001 Dec 28;174(2):141-50. (PMID: 11689289) Int J Cancer. 2006 Nov 1;119(9):2084-9. (PMID: 16841329) Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):40-8. (PMID: 14744731) Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Nov;1865(11):158652. (PMID: 32035228) J Nutr. 1995 Dec;125(12):3081-6. (PMID: 7500187) Hepatobiliary Surg Nutr. 2013 Oct;2(5):252-9. (PMID: 24570955) Mol Nutr Food Res. 2012 Feb;56(2):241-50. (PMID: 22147584) J Hepatol. 2013 Apr;58(4):785-91. (PMID: 23211317) J Biol Chem. 2006 Jul 14;281(28):19327-38. (PMID: 16672231) Nature. 2005 Mar 3;434(7029):113-8. (PMID: 15744310) Am J Physiol Endocrinol Metab. 2014 Jun 1;306(11):E1264-73. (PMID: 24735884) FASEB J. 2011 Mar;25(3):948-59. (PMID: 21106934) Cancer Prev Res (Phila). 2013 Dec;6(12):1304-16. (PMID: 24085778) J Nutr. 2012 Mar;142(3):405-10. (PMID: 22259190) J Nutr. 2019 Sep 1;149(9):1553-1564. (PMID: 31212314) Mol Nutr Food Res. 2020 Feb;64(3):e1900949. (PMID: 31891208) Clin Mol Hepatol. 2013 Sep;19(3):210-5. (PMID: 24133660) J Lipid Res. 2013 Jul;54(7):1719-30. (PMID: 23667178) PLoS One. 2014 May 23;9(5):e98294. (PMID: 24858832) Cancer Prev Res (Phila). 2012 Jul;5(7):952-62. (PMID: 22659145) Int J Cancer. 2014 Dec 15;135(12):2930-9. (PMID: 24771392) Arch Biochem Biophys. 2011 Feb 1;506(1):109-21. (PMID: 21081106) J Agric Food Chem. 2011 Dec 14;59(23):12342-51. (PMID: 22085304) Biofactors. 2013 Mar-Apr;39(2):151-63. (PMID: 23281051) Nutr Res. 2013 Sep;33(9):733-42. (PMID: 24034573) Sci Rep. 2017 Nov 7;7(1):14624. (PMID: 29116185) Cold Spring Harb Perspect Biol. 2012 Dec 01;4(12):. (PMID: 23209156) Cancer Prev Res (Phila). 2011 Aug;4(8):1255-66. (PMID: 21421799) Yakugaku Zasshi. 2012;132(8):903-9. (PMID: 22864348) J Nutr. 2015 Feb;145(2):268-76. (PMID: 25644347) Cancer Prev Res (Phila). 2013 Apr;6(4):309-20. (PMID: 23275008) Nutrients. 2014 Jan 27;6(2):466-88. (PMID: 24473231) J Biol Chem. 2007 Nov 16;282(46):33553-33561. (PMID: 17855355) ACS Chem Biol. 2018 Aug 17;13(8):2121-2129. (PMID: 29883100) Br J Nutr. 2003 Oct;90(4):795-801. (PMID: 13129448) Methods. 2001 Dec;25(4):402-8. (PMID: 11846609) Aging Cell. 2013 Dec;12(6):950-4. (PMID: 23815295) Cancer Prev Res (Phila). 2018 Dec;11(12):797-810. (PMID: 30446518) Int J Biol Sci. 2017 Jul 6;13(7):852-867. (PMID: 28808418) Hepatology. 2012 Oct;56(4):1319-30. (PMID: 22531980) Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12861-6. (PMID: 17646659) Front Neurol. 2011 Nov 23;2:67. (PMID: 22131983) J Biol Chem. 2013 Nov 22;288(47):34081-34096. (PMID: 24106281) Public Health Nutr. 2007 Oct;10(10A):1132-7. (PMID: 17903321) |
| فهرسة مساهمة: | Keywords: fatty liver; oxygenases; β-cryptoxanthin (BCX) |
| تواريخ الأحداث: | Date Created: 20220425 Latest Revision: 20230623 |
| رمز التحديث: | 20230623 |
| مُعرف محوري في PubMed: | PMC9023830 |
| DOI: | 10.21037/hbsn-20-404 |
| PMID: | 35464265 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2304-3881 |
|---|---|
| DOI: | 10.21037/hbsn-20-404 |